Tokyo, Dec 27, 2011 (JCN) - Toray Industries Inc., Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd have agreed to discontinue the joint development program of nalfurafine hydrochloride (Toray development code TRK-820), a drug targeted at pruritus associated with chronic liver disease. This announcement follows Torii's recent decision to concentrate its efforts on the sales of REMITCH in its key therapeutic area of renal/hemodialysis.
The three companies have been marketing REMITCH CAPSULES 2.5 µg (nalfurafine hydrochloride) since March 2009 in Japan. REMITCH is an oral antipruritus drug for hemodialysis patients.
The TRK-820 development is currently in Phase III. Toray will continue the development on its own to maximize the potential of the drug in the hepatic disease area, where the company shows proven bushiness performance.
Torii will continue to market REMITCH CAPSULES 2.5 µg antipruritus drug for hemodialysis patients. In addition, all three companies will continue to cooperate in nurturing the drug.
Copyright © 2013 JCN. All rights reserved. A division of Japan Corporate News Network KK.
 Company Profile |  Print |  Alerts
|
 |
|
Toray, Japan Tobacco and Torii Terminate the Joint Development of Nalfurafine Hydrochloride for Pruritus
(Dec 27, 2011)
|
|
|
JT Launches "Zerostyle Mint" Smokeless Tobacco Product
(Mar 20, 2010)
|
|
|
Japan Tobacco Logs Record 1st-Half Sales
(Oct 30, 2008)
|
|
|
Japan Tobacco Wins Tax Suit in Russia
(Oct 27, 2008)
|
|
|
Japan Tobacco to Sell Aussie Chilled Foods Unit
(Aug 7, 2008)
|
|
|
Japan Tobacco's Sales Grow 40 Pct on Rival Acquisitions
(July 31, 2008)
|
|
|
Japan Tobacco Recalling 40,000 Giveaway Ashtrays
(June 23, 2008)
|
|
|
Japan Tobacco to Close Kanazawa Plant
(Apr 10, 2008)
|
|
|
Japan Tobacco May Cancel Biz with Tianyang Food
(Mar 5, 2008)
|
|
|
JT Sees Record Profits, Poisoning Impact Uncounted
(Feb 7, 2008)
|
|
|
|
|
|
|
Otsuka Launches First Skin Patch Treatment for Parkinson's Disease and Restless Legs Syndrome (Feb 22, 2013)
|
|
|
Teijin Launches Polyester Curtain Fabric with Enhanced Pollen-trapping (Feb 21, 2013)
|
|
|
Toyota Tsusho Opens Medical Clinic in Thai Plant (Feb 18, 2013)
|
|
|
Daiichi Sankyo Develops Nucleic Acid Treatment for Duchenne Muscular Dystrophy (Feb 15, 2013)
|
|
|
Dainippon Sumitomo Pharma Opens Subsidiary in Singapore (Jan 22, 2013)
|
|
|
Teijin and InCube Labs Enter Strategic Partnership in Healthcare Business (Jan 22, 2013)
|
|
|
Chugai Grants Debiopharm Group Exclusive Worldwide License for Anti-cancer Agent (Jan 9, 2013)
|
|
|
Takara Bio Initiates Phase 1 HIV Gene Therapy Clinical Trial (Jan 7, 2013)
|
|
|
Kobe University, KNC Labs and Dainippon Sumitomo to Research Anti-cancer Agent (Dec 28, 2012)
|
|
|
Daiichi Sankyo Introduces Alzheimer's Disease Awareness Campaign (Dec 20, 2012)
|
More Drugs & OTC news...
|
|
|
|
|
|
Otsuka Launches First Skin Patch Treatment for Parkinson's Disease and Restless Legs Syndrome (Feb 22, 2013)
|
|
|
Teijin Launches Polyester Curtain Fabric with Enhanced Pollen-trapping (Feb 21, 2013)
|
|
|
Toyota Tsusho Opens Medical Clinic in Thai Plant (Feb 18, 2013)
|
|
|
Daiichi Sankyo Develops Nucleic Acid Treatment for Duchenne Muscular Dystrophy (Feb 15, 2013)
|
|
|
Dainippon Sumitomo Pharma Opens Subsidiary in Singapore (Jan 22, 2013)
|
|
|
Teijin and InCube Labs Enter Strategic Partnership in Healthcare Business (Jan 22, 2013)
|
|
|
Chugai Grants Debiopharm Group Exclusive Worldwide License for Anti-cancer Agent (Jan 9, 2013)
|
|
|
Takara Bio Initiates Phase 1 HIV Gene Therapy Clinical Trial (Jan 7, 2013)
|
|
|
Kobe University, KNC Labs and Dainippon Sumitomo to Research Anti-cancer Agent (Dec 28, 2012)
|
|
|
Daiichi Sankyo Introduces Alzheimer's Disease Awareness Campaign (Dec 20, 2012)
|
More Medical news...
|
|
